Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Phase 1 Recruiting 5 enrolled Akros Pharma Inc. PPD Development, LP · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)

Timeline

Start: 2026-02-02
Primary completion: 2026-06
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JTE-162	Unknown	—	—

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Summary

Timeline

Drugs

Indications